- Home
- MRK vs NVS Comparison
MRK vs NVS Comparison
Compare MRK & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- NVS
- Stock Information
- Founded
- MRK 2000
- NVS 1895
- Country
- MRK United States
- NVS Switzerland
- Employees
- MRK N/A
- NVS N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- MRK Health Care
- NVS Health Care
- Exchange
- MRK Nasdaq
- NVS Nasdaq
- Market Cap
- MRK 218.8B
- NVS 254.8B
- IPO Year
- MRK N/A
- NVS 1991
- Fundamental
- Price
- MRK $91.49
- NVS $131.71
- Analyst Decision
- MRK Buy
- NVS Sell
- Analyst Count
- MRK 15
- NVS 4
- Target Price
- MRK $105.29
- NVS $118.00
- AVG Volume (30 Days)
- MRK 10.7M
- NVS 1.6M
- Earning Date
- MRK 10-30-2025
- NVS 10-28-2025
- Dividend Yield
- MRK 3.56%
- NVS 1.96%
- EPS Growth
- MRK 58.08
- NVS N/A
- EPS
- MRK 7.56
- NVS 7.30
- Revenue
- MRK $64,235,000,000.00
- NVS $56,372,000,000.00
- Revenue This Year
- MRK $1.82
- NVS $9.44
- Revenue Next Year
- MRK $5.10
- NVS $2.65
- P/E Ratio
- MRK $12.04
- NVS $18.12
- Revenue Growth
- MRK 1.68
- NVS 12.88
- 52 Week Low
- MRK $73.31
- NVS $96.06
- 52 Week High
- MRK $105.07
- NVS $133.55
- Technical
- Relative Strength Index (RSI)
- MRK 67.81
- NVS 63.16
- Support Level
- MRK $82.01
- NVS $126.00
- Resistance Level
- MRK $88.30
- NVS $127.11
- Average True Range (ATR)
- MRK 2.18
- NVS 1.63
- MACD
- MRK 0.47
- NVS 0.46
- Stochastic Oscillator
- MRK 87.57
- NVS 99.22
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.